Valproic Acid Issues

While valproic acid can offer an effective treatment solution for several health conditions including epileptic seizures, there are some issues associated with its use.

These include all women of childbearing age due the congenital effects of the medication, as well as people at risk of pancreatitis, kidney disease and liver disease. Additionally, some people experience a hypersensitive reaction to valproate therapy, which can result if serious issues.

In Pregnancy

Valproic acid is known to cause major congenital malformations when some women take the medication throughout pregnancy. Neural tube defects such as spina bifida are the main concern, but valproic acid may also negatively affect cognitive test scores when a child is exposed to the medication in the uterus.

As a result, valproate should only be used as last-line therapy for pregnant women with epilepsy, when other medications have failed to prevent seizures or cause intolerable adverse effects for the patient. Where possible, making a substitution for an alternative medication is always recommended. If, however, it is necessary to continue with valproate therapy, high-dose folic acid supplementation is recommended, as this helps to counteract the folate antagonist effect of the drug.

In addition, the risk of all women of childbearing age to become pregnant while taking therapy with valproate should be considered. This is essential as the congenital effects of valproate primarily occur in the first trimester, commonly before the woman is aware she is pregnant and able to find an alternative therapy for valproate. For this reason, every sexually active woman of childbearing age taking valproic acid should use adequate contraception during therapy to reduce the possibility of an unexpected pregnancy.

Pancreatitis

Both children and adults taking valproic acid therapy have reported serious cases of pancreatitis, which can be fatal in some cases. Symptoms and effects may emerge shortly following initiation of therapy, or be delayed after taking the medication for several years with negligible adverse effects.

Indicative signs of pancreatitis that should prompt patients to see a medical professional as soon as possible include:

• Abdominal pain
• Nausea
• Vomiting
• Anorexia

If pancreatitis is suspected, immediate medical evaluation is required and valproic acid therapy should be discontinued.

Kidney or Liver Disease

Any renal or hepatic dysfunction is likely to affect the clearance and effect of sodium valproate and may also result in failure of one of these major organs.

Patients that have a medical history or strong family history of these diseases should proceed with valproate therapy with caution, depending on their specific benefits and risks of treatment. Additionally, young children less that two years of age have a higher risk of hepatotoxicity that could lead to fatal results, particularly those with multiple drug therapies.

Hypersensitivity

Some patients may also experience adverse effects due to a hypersensitivity reaction to the medication. These effects commonly become evident shortly after taking the first dose, although they may be delayed in some cases and present a few weeks later.

Signs of an allergic reaction to valproic acid include skin rash, itching, fever, swelling, shortness of breath, a runny nose and watery eyes. In severe cases of anaphylaxis, patients may notice signs of:

• Difficulty breathing due to tightened airways
• Nausea and cramping
• Vomiting and diarrhea
• Tachycardia
• Hypotension
• Seizure or loss of consciousness

If hypersensitivity to valproate is suspected, the patient should seek immediate medical attention to manage the effects. Subsequent doses of the medication should be withheld until the cause of the effects is known with certainty and, if hypersensitivity if responsible, an alternative therapy should be recommended.

References

• http://reference.medscape.com/drug/depakene-stavzor-valproic-acid-343024#5
• http://www.drugs.com/pro/valproate.html
• http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140754/